Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, ...

Edwin Posadas discusses RTOG 3506 (STEEL), a phase II trial adding enzalutamide to salvage radiation plus two years of androgen deprivation therapy in extremely high-risk post-pro ...

Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancements in upper tract urothelial carcinoma ...

Dr. Maluf emphasized that his discussion would focus on penile squamous cell carcinoma and genitourinary basket trials. At ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a managing advanced disease in renal ...

This is the largest study exploring how we should treat people who present at A&E with blood in their urine. It’s a common problem affecting thousands of people around the world, and these patients ...

Germline testing can identify hereditary cancer, which leads to implications for family members, cascade testing for relatives, and starting surveillance and prevention measures: Genetic testing in ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Himisha Beltran discussing how to read a ...

The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...

(UroToday.com) The 2026 European Association of Urology (EAU) Annual Meeting held in London, U.K., was host to the Hormone sensitive metastatic prostate cancer: Thematic Session. Dr. Declan Murphy ...

Padeliporfin VTP has demonstrated safety and efficacy for upper tract urothelial carcinoma treatment in a phase 1 study. Padeliporfin VTP is a combination product of a drug, padeliporfin administered ...